IMCCHealthcare · Drug Manufacturers - Specialty & Generic

IMCC Stock Forecast: IM Cannabis Corp. Price Predictions for 2026-2027

Last close, 7 Oct 2026

$1.90

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 7 Oct 2026 — in the weakest quartile.

Market cap

$3.2M

Ticker Nerd rank

20 / 100

Median analyst target

—

Analysts covering

Revenue$8.7M−30.6% y/y

Operating income−$1.7M

Net income−$2.5M

Free cash flow−$191K

Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown

Ticker Nerd rank

IMCC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores IM Cannabis Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026

20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Issuance

Revisions

Quality

Momentum

Value

Volatility

Growth

Size (98): Smaller than most of the companies we track.

Growth (5): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMCC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMCC, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts

0 Buy1 Hold0 Sell

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
31 Dec 2021	Roth Capital	Initiates	Buy	—
5 Oct 2021	Roth Capital	Initiates	Buy	—
10 June 2021	Alliance Global Partners	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMCC appears on the weeks it earns a place.

Estimates

IMCC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

IM Cannabis Corp. (IMCC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.7×
Price / sales: 0.1×
Price / book: −3.5×
EV / EBITDA: −1.6×

Growth & margins

Revenue growth (YoY): −40.2%
Earnings growth (YoY): −30.6%
Gross margin: 16.3%
Operating margin: −27.5%
Net margin: −39.1%

Returns & dividend

Return on equity: 313.1%
Return on assets: −18.6%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

IM Cannabis Corp. (IMCC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

IM Cannabis Corp. has a market value of $3.2M and an enterprise value of $9.3M.
Revenue in the twelve months to 31 Mar 2026: $50.9M. The latest quarter shrank 40.2% year on year.
Net income over the same four quarters: −$14.4M, a −28.3% net margin.
Free cash flow in the twelve months to 31 Mar 2026: $49K, after $18K of capital spending.
IM Cannabis Corp. spent $0.0 on dividends in the twelve months to 31 Mar 2026.
Shares outstanding: 1.6M.
Trailing P/E: −0.7×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
IM Cannabis Corp. employs 44 people — $1.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

IMCC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
IMCCIM Cannabis Corp.	$3.2M	20
SBFMSunshine Biopharma, Inc.	$3.0M	61
PRFXPRF Technologies Ltd.	$2.7M	4
SXTCChina Sxt Pharmaceuticals, Inc.	$3.7M	9
YCBDcbdMD, Inc.	$4.6M	34
SNOASonoma Pharmaceuticals, Inc.	$5.8M	35
GELSGelteq Ltd.	$6.0M	11

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own IM Cannabis Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMCC news & analysis

IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet

PRNewsWire · 29 Sept 2026positive

IM Cannabis Corp. announced the closing of the sale of IMC Holdings and its European-focused operations to Slil.com Holding Ltd., completing a transaction previously announced in June and August 2026. The company said the transaction is expected to result in an improvement of approximately C$3 million in shareholders' equity, strengthening its balance sheet.

Why it matters — This divestiture of its European operations and the resulting C$3 million improvement in shareholders' equity signals a stronger balance sheet for IMCC investors following the completed sale.

IM Cannabis Announces Closing of US$1.31 Million Registered Direct Offering of Common Shares

PRNewsWire · 24 Sept 2026neutral

IM Cannabis Corp. announced the closing of its previously announced registered direct offering, in which it sold and issued 655,000 common shares to accredited investors at US$2.00 per share, bringing aggregate gross proceeds of US$1.31 million before offering expenses.

Why it matters — IMCC watchers would care because the company has completed a capital raise that adds to its available funding.

IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement

PRNewsWire · 23 Sept 2026positive

IM Cannabis Corp. announced that on September 23, 2026, it received written notice from Nasdaq confirming it has regained compliance with the exchange's minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2).

Why it matters — This regulatory milestone removes the risk of delisting from Nasdaq, which is important for investors monitoring IMCC's listing status.

IM Cannabis Announces Pricing of US$1.31 Million Registered Direct Offering of Common Shares

PRNewsWire · 23 Sept 2026neutral

IM Cannabis Corp. has entered into securities purchase agreements with accredited investors to sell 655,000 common shares at US$2.00 per share in a registered direct offering, expected to generate gross proceeds of approximately US$1.31 million at closing before offering expenses. The company operates medical cannabis businesses in Israel and Germany.

Why it matters — This capital-raising announcement is relevant to IMCC watchers as it affects the company's share count and cash position through a new equity offering.

IM Cannabis Enters Non-Binding Agreement to Acquire 51% of Space Defense Innovations, Operating in the European Tactical UAS Market

PRNewsWire · 23 Sept 2026neutral

IM Cannabis Corp. announced it has entered into a non-binding Letter of Intent to acquire 51% of the issued and outstanding equity securities of Space Defense Innovations LLC, a Polish company that distributes advanced tactical UAS and Hybrid Fixed-Wing VTOL-UAS platforms in Europe.

Why it matters — IMCC watchers would care because this signals the company is exploring a potential strategic expansion beyond cannabis into the European tactical unmanned aerial systems market, though the agreement is non-binding at this stage.

FAQ

Frequently asked questions about IMCC stock

Is IMCC stock a buy right now?

Of the 1 analysts covering IM Cannabis Corp., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IM Cannabis Corp. 20 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMCC?

As at 7 Oct 2026, IM Cannabis Corp. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the IMCC stock forecast for 2030?

No analyst covering IM Cannabis Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMCC are extrapolating price history, which says nothing about the business.

What does IM Cannabis Corp. do?

IM Cannabis Corp. is an international medical cannabis company focused on importing, distributing, and selling cannabis-based products for medical patients in Israel and Germany.

What is the latest news on IMCC?

The most recent item we track (PRNewsWire, 29 Sept 2026): "IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet". IM Cannabis Corp. announced the closing of the sale of IMC Holdings and its European-focused operations to Slil.com Holding Ltd., completing a transaction previously announced in June and August 2026. The company said the transaction is expected to result in an improvement of approximately C$3 million in shareholders' equity, strengthening its balance sheet.

Company

About IM Cannabis Corp.

IM Cannabis Corp. is an international medical cannabis company focused on importing, distributing, and selling cannabis-based products for medical patients in Israel and Germany. The company offers dried flower and full-spectrum cannabis extract products under brands including IMC, BLKMT, and LOT420, with a business model centered on regulated medical markets and pharmacy-based supply chains. Its operations include product sourcing, quality control, and market-specific distribution across Europe and the Middle East, supporting physicians, pharmacies, and patients who rely on standardized cannabis formulations. IM Cannabis Corp. also maintains an online and retail presence tied to its medical cannabis ecosystem, reinforcing its role as a specialized supplier within the healthcare and life sciences sectors. Headquartered in Kibbutz Glil-Yam, Israel, the company remains positioned as a focused participant in the growing regulated medical cannabis market.

CEO Mr. Oren Shuster · 44 employees · Canada · https://imcannabis.com